A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/08/2004	EP1484055A1 Delivery system with increased bioavailability
12/08/2004	EP1484054A1 Drug delivery system for the subconjunctival administration of fine grains
12/08/2004	EP1484053A2 Percutaneously applicable preparation and suppository containing an antidementia medicament
12/08/2004	EP1483973A1 Fat or oil composition
12/08/2004	EP1483396A2 Wit 3.0, novel gene to control soft tissue wound healing
12/08/2004	EP1483384A2 Method for overexpression of zwitterionic polysaccharides
12/08/2004	EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo
12/08/2004	EP1483366A1 Antimicrobial composition
12/08/2004	EP1483292A1 Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
12/08/2004	EP1483289A2 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
12/08/2004	EP1483285A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME
12/08/2004	EP1483281A1 Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
12/08/2004	EP1483271A1 Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
12/08/2004	EP1483270A1 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
12/08/2004	EP1483269A1 Racemization and enantiomer separation of clopidogrel
12/08/2004	EP1483268A2 Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
12/08/2004	EP1483267A2 Microtubule stabilizing compounds
12/08/2004	EP1483266A1 Spiro compounds with npy antagonistic activity
12/08/2004	EP1483265A1 Purine derivatives as kinase inhibitors
12/08/2004	EP1483263A1 Thiazolyl urea compounds for the treatment of cancer
12/08/2004	EP1483261A1 Phthalimide carboxylic acid derivatives
12/08/2004	EP1483260A1 Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
12/08/2004	EP1483258A1 Benzimidazole-derivatives for the treatment of sexual dysfunction
12/08/2004	EP1483257A1 Quinazoline compounds useful in therapy
12/08/2004	EP1483254A1 Resistance-repellent retroviral protease inhibitors
12/08/2004	EP1483253A1 An antimicrobial agent
12/08/2004	EP1483251A1 C3-cyano epothilone derivatives
12/08/2004	EP1483247A2 Aryl substituted pyrimidines and the use thereof
12/08/2004	EP1483244A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
12/08/2004	EP1483242A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
12/08/2004	EP1483240A1 Indolamid derivatives which possess glycogen phosphorylase inhibitory activity
12/08/2004	EP1483239A2 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
12/08/2004	EP1483237A2 Tropane compounds
12/08/2004	EP1483236A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists
12/08/2004	EP1483233A2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use
12/08/2004	EP1483232A1 Salts of nateglinide
12/08/2004	EP1483231A1 Novel cinnamate salts, method for production and use thereof as medicaments
12/08/2004	EP1483228A1 Nk1 antagonists
12/08/2004	EP1482995A1 Composition and method for coating medical devices
12/08/2004	EP1482988A1 METHOD OF RADIO−LABELLING BIOMOLECULES
12/08/2004	EP1482984A2 Surrogate antibodies and methods of preparation and use thereof
12/08/2004	EP1482983A2 Non-myeloablative tolerogenic treatment with tyrphostins
12/08/2004	EP1482980A1 Prostaglandin composition for the treatment of erectile dysfunction
12/08/2004	EP1482978A1 Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
12/08/2004	EP1482977A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells
12/08/2004	EP1482976A1 A preparation and method for weight reduction
12/08/2004	EP1482975A2 Prevention of tissue adhesion
12/08/2004	EP1482972A2 Treatment of immunological disorders using anti-cd30 antibodies
12/08/2004	EP1482971A1 Strategy for retroviral immunotherapy
12/08/2004	EP1482970A1 Cancer therapy
12/08/2004	EP1482964A1 Use of egfr transactivation inhibitors in human cancer
12/08/2004	EP1482962A2 Method of treating trx mediated diseases
12/08/2004	EP1482956A1 Targeted drug delivery methods
12/08/2004	EP1482955A1 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
12/08/2004	EP1482954A2 Alpha-substituted arylalkyl phosphonate derivatives
12/08/2004	EP1482953A1 Alpha-substituted heteroarylalkyl phosphonate derivattives
12/08/2004	EP1482952A2 Therapeutic and prophylactic treatment of aging and disorders of aging in humans
12/08/2004	EP1482951A1 Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses
12/08/2004	EP1482950A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
12/08/2004	EP1482949A1 Sulfatase inhibiting progestogen-only contraceptive regimens
12/08/2004	EP1482948A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy
12/08/2004	EP1482947A1 Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
12/08/2004	EP1482946A1 Progesterone oral drug delivery system
12/08/2004	EP1482944A2 N3 alkylated benzimidazole derivatives as mek inhibitors
12/08/2004	EP1482943A2 Dosing regimen for gemcitabine hcv therapy
12/08/2004	EP1482942A2 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
12/08/2004	EP1482941A1 Beta-sheet mimetics and composition and methods relating thereto
12/08/2004	EP1482940A2 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
12/08/2004	EP1482939A1 Preparation of paroxetine involving novel intermediates
12/08/2004	EP1482938A1 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
12/08/2004	EP1482937A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
12/08/2004	EP1482936A1 Ophthalmic composition comprising ascomycin
12/08/2004	EP1482935A1 Thiazole and oxazole derivatives which modulate ppar activity
12/08/2004	EP1482934A1 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases
12/08/2004	EP1482933A2 Potent, simplified derivatives of immunosuppressive agents
12/08/2004	EP1482932A1 N3 alkylated benzimidazole derivatives as mek inhibitors
12/08/2004	EP1482931A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/08/2004	EP1482930A1 Peptide deformylase inhibitors
12/08/2004	EP1482929A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
12/08/2004	EP1482928A2 Mediators of hedgehog signaling pathways,compositions and uses related thereto
12/08/2004	EP1482927A1 Method of treating osteoarthritis
12/08/2004	EP1482926A2 Amino-methyl substituted tetracycline compounds
12/08/2004	EP1482925A1 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl!-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
12/08/2004	EP1482924A2 Cathepsin cysteine protease inhibitors
12/08/2004	EP1482923A1 Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process
12/08/2004	EP1482922A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
12/08/2004	EP1482921A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
12/08/2004	EP1482920A1 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
12/08/2004	EP1482919A1 Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
12/08/2004	EP1482918A2 Utilization of ubiquinones for influencing the effect of histamine
12/08/2004	EP1482917A1 Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
12/08/2004	EP1482916A2 Schwann cell and phosphodiesterase inhibitors based therapy
12/08/2004	EP1482912A2 Naltrexone hydrochloride compositions
12/08/2004	EP1482897A2 Aminodiphosphonate apolipoprotein e modulators
12/08/2004	EP1482896A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482895A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482796A1 Stable compositions comprising tezacitabine
12/08/2004	EP1482795A1 New immunoeffector compounds
12/08/2004	EP1482794A1 Method of treatment or prevention of obesity
12/08/2004	EP1482791A1 Antimicrobial therapeutic compositions and methods of use

1 ... 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883 4884 4885 4886 ... 7860